One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

When Nicole Stovall stepped into her new role as Chief Diversity Officer at Merck, it wasn’t just another career milestone—it was the manifestation of years of purpose, persistence, and faith […] ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that ...

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in the past 3 months, drawing fresh attention to its valuation. See our latest ...

Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, on Dec. 4 announced the Food and Drug Administration ...